Clinical trials: sponsored by Incyte Corporation
Atopic Dermatitis (AD)
Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis
The purpose of this study is to evaluate the long-term safety and tolerability of ruxolitinib cream in adolescents with Atopic Dermatitis (AD).
- Trial name
- NCT05456529
- Testing
- Ruxolitinib Cream
- Where
- 38 sites in United States, Canada and 1 more
- Volunteers
- 103 people
- Sponsor
- Incyte Corporation
Healthy Participants
Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, & Food Effect of Oral INCB000631 to Healthy Adult Participants
This study will be conducted to assess the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics, and Food Effect of INCB000631 When Administered Orally to Healthy Adult Participants.
- Trial name
- NCT06775327
- Testing
- INCB000631
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Healthy Volunteers
A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants
The purpose of this study is to evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants.
- Trial name
- NCT06941077
- Testing
- INCB057643
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)
The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children with Atopic Dermatitis. This is a randomized, double-blind, Vehicle Controlled study.
- Trial name
- NCT04921969
- Testing
- Ruxolitinib, Vehicle Cream
- Where
- 67 sites in United States, Canada
- Volunteers
- 330 people
- Sponsor
- Incyte Corporation
Lymphoma
A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor
This is a Phase 2, open-label, 2-cohort study designed to evaluate the efficacy and safety of 2 parsaclisib treatment regimens in participants with relapsed or refractory mantle cell lymphoma (MCL) previously treated either with…
- Trial name
- (CITADEL-205) (NCT03235544)
- Testing
- Parsaclisib
- Where
- 103 sites in United States, Belgium and 9 more
- Volunteers
- 162 people
- Sponsor
- Incyte Corporation
Lymphoma
A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma
The purpose of this study is to assess the objective response rate of parsaclisib treatment in participants with relapsed or refractory follicular lymphoma.
- Trial name
- CITADEL-203 (NCT03126019)
- Testing
- Parsaclisib
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 126 people
- Sponsor
- Incyte Corporation
Non Small Cell Lung Cancer, Urothelial Cancer
Study of INCB086550 in Select Solid Tumors
An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors
- Conditions
- Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT04629339
- Testing
- INCB086550
- Where
- 20 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 16 people
- Sponsor
- Incyte Corporation
Vitiligo
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo
The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream with or without phototherapy in adolescent and adult participants with non-segmental vitiligo for whom vitiligo area (facial and nonfacial)…
- Trial name
- NCT05247489
- Testing
- Ruxolitinib 1.5% cream, NB-UVB phototherapy
- Where
- 13 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- Incyte Corporation
Melanoma, Hepatocellular Carcinoma (HCC)
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants with select solid tumors.
- Conditions
- Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC), Microsatellite Instability - High (MSI-H)
- Trial name
- NCT05909995
- Testing
- INCB 99280 with Ipilimumab
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 8 people
- Sponsor
- Incyte Corporation
Healthy Participants
A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants
This study is conducted to determine the Bioequivalence of Ruxolitinib XR 55 mg Tablets With Ruxolitinib IR Tablets Administered Orally in Healthy Participants
- Trial name
- NCT06555081
- Testing
- Ruxolitinib IR, Ruxolitinib XR
- Where
- United States
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Healthy Participants
A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants
The purpose of this study is to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult…
- Trial name
- NCT06416800
- Testing
- Digoxin, Rosuvastatin, Metformin
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa
Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream in participants with Hidradenitis Suppurativa.
- Trial name
- NCT05635838
- Testing
- Ruxolitinib cream, Vehicle cream
- Where
- 20 sites in United States, Canada
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation
Cutaneous Lichen Planus
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus
The purpose of this study will be to evaluate efficacy and safety of Ruxolitinib cream in participants With Cutaneous Lichen Planus.
- Trial name
- NCT05593432
- Testing
- Ruxolitinib cream, Vehicle cream
- Where
- 24 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Incyte Corporation
Healthy Participants
A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants
The purpose of this study is to measure the effect of multiple doses of orally administered povorcitinib on skin PK and to characterize plasma PK parameters of povorcitinib following multiple doses of orally administered…
- Trial name
- NCT06505265
- Testing
- Povorcitinib
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Healthy Participants
A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants
The purpose of this study is to evaluate the effect of povorcitinib on the QT/QTc Interval in healthy participants.
- Trial name
- NCT06441318
- Testing
- Povorcitinib, Moxifloxacin
- Where
- United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Lichen Sclerosus
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus
The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream in participants With Lichen Sclerosus. This is randomized, double-blind, vehicle-controlled (DBVC) study with a DBVC period of 12 weeks…
- Trial name
- NCT05593445
- Testing
- Ruxolitinib cream, Vehicle cream
- Where
- 14 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- Incyte Corporation
Advanced Malignancies
The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
Safety and tolerability of pemigatinib.in monotherapy or combination in patients that have participated in a previous parent study to treat advanced malignancies.
- Trial name
- NCT04949191
- Testing
- Pemigatinib, Retifanlimab, Pembrolizumab
- Where
- 10 sites in United States, Denmark and 2 more
- Volunteers
- 10 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement
This is a randomized, double blind, vehicle controlled Phase 2 study with a 4-week open label extension in adolescent and adult participants with atopic dermatitis and head and/or neck involvement.
- Trial name
- NCT05127421
- Testing
- Ruxolitinib cream, Vehicle
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Incyte Corporation
Healthy Participants
A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females
The purpose of this study is to evaluate the drug interaction between povorcitinib and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females.
- Trial name
- NCT06380205
- Testing
- Povorcitinib, Levonorgestrel/Ethinyl estradiol
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Healthy Participants
A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.
This study is conducted to determine the Relative Bioavailability of Ruxolitinib XR Tablets Compared With Ruxolitinib IR Tablets Administered Orally in Healthy Participants.
- Trial name
- NCT06310304
- Testing
- Ruxolitinib IR, Ruxolitinib XR
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation